An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

This study tests a CAR-T cell therapy called SCAR02 (targeting both BCMA and CD19) in patients with severe, treatment-resistant autoimmune diseases including rheumatoid arthritis, lupus (SLE), Sjögren's syndrome (dry syndrome), and systemic sclerosis (scleroderma). **You may be eligible if...** - You are 18 or older with one of the autoimmune diseases listed (RA, SLE, Sjögren's, or systemic sclerosis) - Your disease remains active despite standard and advanced treatments - Your blood counts, liver, kidney, and clotting function meet minimum requirements - For RA: your disease activity is elevated and you have been on stable conventional DMARDs - For SLE: your disease is active with a SLEDAI score ≥ 8 despite standard treatment - For Sjögren's or systemic sclerosis: your disease is progressive despite conventional therapy **You may NOT be eligible if...** - You have serious brain or nervous system conditions (stroke, epilepsy, dementia, etc.) - You have significant heart disease (heart attack, heart failure, angina) - You have had an organ or bone marrow transplant - You have active or suspected serious infection (bacterial, viral, or fungal) - You have a history of cancer - You have active hepatitis B, hepatitis C, HIV, syphilis, CMV, or EBV infections - You are pregnant, breastfeeding, or planning pregnancy within 2 years Talk to your doctor to see if this trial is right for you.